TNF inhibitor

      Can IL-17F signalling be modulated by treatment with TNFi?
      In PsA pts non responders to previous TNFi, there was increas

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz
      Worried about cancer risk with ts/bDMARDs in RA?

      Real-world data from over 4,600 patients says: don’t be. No increase

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Worried about cancer risk with ts/bDMARDs in RA? Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up. Abstract#OP0065 @RheumNow #EULAR2025
      Early intensive therapy in PsA.
      STAMP RCT in early PsA:
      •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
      •MDA at

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX
      Should we start strong in PsA?

      In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Should we start strong in PsA? In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w. Abstract#OP0089 @RheumNow #EULAR2025

      Catch up on Conference Podcasts

      ×